ThermoGenesis Announces Strategic Reorganization Initiative

barbara.lempert Company to Focus on Expanding Its AXP AutoXpress Platform Functionality for Cord Blood and Cell Therapy Applications RANCHO CORDOVA, Calif., Oct. 30, 2013 (GLOBE NEWSWIRE) ...

Sanofi, Merrimack cancer drug flops (again) in second round of PhII program

John Carroll Seven months after a mid-stage cancer drug from Sanofi and Merrimack Pharmaceuticals flunked its first mid-stage test, researchers are back with another failure to report. ...

Dendreon’s for sale. Will anyone step up to battle for Provenge?

Tracy Staton Just a few days ago, we learned that Dendreon is looking to woo a buyer. The question now is whether the struggling drugmaker can find a suitor to take on its baggage. FiercePharma ...

Vaccine plant problems put Sanofi shot supplies in dire straits

Tracy Staton Last year, the FDA came down hard on a Sanofi Pasteur plant in Toronto. The ensuing trouble triggered serious supply problems–and, in turn, a shortage of childhood ...

InterMune Reports Third Quarter 2013 Financial Results And Business Highlights

barbara.lempert — Reports 8th Consecutive Quarter of Esbriet Revenue Growth — BRISBANE, Calif., Oct. 30, 2013 /PRNewswire/ — InterMune, Inc. (NASDAQ: ITMN) today ...

Amarin suffers another blow at the hands of the FDA

John Carroll Already suffering from an expert panel rejection for an expanded label on its cholesterol drug Vascepa, Amarin was subjected to another drubbing on Wall Street after the ...

Pfizer aims ambitious PCSK9 program at payers, skeptical regulators

Tracy Staton Tantalized by various megablockbuster projections for the PCSK9 field of cholesterol drugs, Pfizer has mapped out one of the most ambitious late-stage programs ...

Depomed Launches Lazanda

barbara.lempert Signature SupportTM Program offers a full-range of services to simplify coverage support and patient assistance for patients taking Lazanda NEWARK, Calif., Oct. 28, ...

Study: Drug developers routinely–and unethically–leave trial data in the dark

John Carroll Drug companies routinely herald their concern for patients as the leading reason why they spend billions of dollars on drug research. But a new study questions Big Pharma's ...

Gilead prepares for anticipated hep C drug approval with plant expansion

Carly Helfand If the FDA takes the recommendation from a panel that voted 15-0 last week to approve hep C treatment sofosbuvir, maker Gilead will be ready. FiercePharma News

FDA bans suck sales out of Ranbaxy, Wockhardt

Eric Palmer Import bans imposed against two of India's largest generic drugmakers are already shaving away their financial performance, even though the worst is yet to come. Both ...

StemCells, Inc. Acquires Seminal Neural Stem Cell Patent Portfolio

barbara.lempert NEWARK, Calif., Oct. 29, 2013 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) today announced the acquisition of a portfolio of issued US and Canadian patents ...
Page 1 of 2212345...1020...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS